ArticleSurgical case reports2025
Mycophenolate Mofetil for Steroid-Refractory Immune-Related Hepatitis and Sclerosing Cholangitis Following Neoadjuvant Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Case Report.
Article in Surgical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNeoadjuvant chemoimmunotherapy is increasingly regarded as the standard treatment for resectable non-small cell lung cancer. Although it improves survival outcomes, immune-related adverse events can delay or prevent curative surgery. Optimal strategies for managing these adverse events in the preoperative setting remain unclear. This case is notable for being, to the best of our knowledge, the first to report curative surgery following treatment of neoadjuvant chemoimmunotherapy-induced, steroid-refractory immune-related hepatitis using mycophenolate mofetil. CASE PRESENTATION: A 74-year-old man with stage IIIA (cT2bN2M0) squamous cell carcinoma of the right lower lobe received neoadjuvant chemoimmunotherapy consisting of carboplatin, paclitaxel, and nivolumab. Following 2 treatment cycles, he developed fever, jaundice, and grade 3 liver dysfunction. Laboratory and imaging studies revealed features consistent with hepatitis and sclerosing cholangitis, suspected to be immune-related. High-dose corticosteroids were administered, resulting in only transient improvement. Owing to steroid-refractory disease, mycophenolate mofetil was initiated, leading to normalization of liver function and resolution of symptoms. However, the primary tumor exhibited regrowth following immunosuppression. Surgical resection was performed, consisting of right middle and lower lobectomy with lymph node dissection. Histopathology confirmed ypT1cN0M0 stage IA3 with 50% residual viable tumor. The postoperative course was complicated by persistent air leakage, empyema, and a bronchial fistula, ultimately requiring open-window thoracostomy. The patient was discharged and remains free of disease recurrence at follow-up.
conclusionsThis case highlights the potential role of mycophenolate mofetil in managing steroid-refractory immune-related liver injury induced by neoadjuvant chemoimmunotherapy in non-small cell lung cancer. Although immunosuppressive therapy may enable definitive surgery, it may also contribute to tumor regrowth and serious postoperative complications. As the use of neoadjuvant chemoimmunotherapy expands, further clinical experience is needed to guide the management of immune-related adverse events and ensure safe and effective surgical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.